ACBD5 deficiency causes a defect in peroxisomal very long-chain fatty acid metabolism
Open accessAbstract
Background: Acyl-CoA binding domain containing protein 5 (ACBD5) is a peroxisomal membrane protein with a cytosolic acyl-CoA binding domain. Because of its acyl-CoA binding domain, ACBD5 has been assumed to function as an intracellular carrier of acyl-CoA esters. In addition, a role for ACBD5 in pexophagy has been suggested. However, the precise role of ACBD5 in peroxisomal metabolism and/or functioning has not yet been established. Previously, a genetic ACBD5 deficiency was identified in three siblings with retinal dystrophy and white matter disease. We identified a pathogenic mutation in ACBD5 in another patient and studied the consequences of the ACBD5 defect in patient material and in ACBD5-deficient HeLa cells to uncover this role. Methods: We studied a girl who presented with progressive leukodystrophy, syndromic cleft palate, ataxia and retinal dystrophy. We performed biochemical, cell biological and molecular studies in patient material and in ACBD5-deficient HeLa cells generated by CRISPR-Cas9 genome editing. Results: We identified a homozygous deleterious indel mutation in ACBD5 , leading to complete loss of ACBD5 protein in the patient. Our studies showed that ACBD5 deficiency leads to accumulation of very long-chain fatty acids (VLCFAs) due to impaired peroxisomal β-oxidation. No effect on pexophagy was found. Conclusions: Our investigations strongly suggest that ACBD5 plays an important role in sequestering C26-CoA in the cytosol and thereby facilitates transport into the peroxisome and subsequent β-oxidation. Accordingly, ACBD5 deficiency is a novel single peroxisomal enzyme deficiency caused by impaired VLCFA metabolism, leading to retinal dystrophy and white matter disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LD_0498 was found to have impaired peroxisomal β-oxidation of C26:0 and genome sequencing revealed a homozygous, 7.5kb deletion in ACBD5 causing loss of exons 7 and 8, confirmed by Sanger sequencing.
“LD_0498 was found to have impaired peroxisomal β‐oxidation of C26:0 and genome sequencing revealed a homozygous, 7.5kb deletion in ACBD5 (OMIM:616618) causing loss of exons 7 and 8, confirmed by Sanger sequencing.22”
From Genome sequencing in persistently unsolved white matter disorders (2020) · cites this paper as [22]
Cognitive impairments were reported in six ACBD5-deficient patients.
“Beyond motor and sensory deficits, cognitive impairments were reported in six patients (Ferdinandusse et al., 2017; Bartlett et al., 2021; Rudaks et al., 2024; Al Shamsi et al., 2025), and delayed language development in five (Ferdinandusse et al., 2017; Bartlett et al., 2021; Gorukmez et al., 2022; Hasturk et al., 2024; Al Shamsi et al., 2025; Supplementary Table 1).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
Rod-cone or cone-rod dystrophies affecting both photoreceptor types were described in at least nine patients.
“Rod-cone or cone-rod dystrophies, affecting both photoreceptor types, were described in at least nine patients”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
All 14 reported patients exhibited reduced psychomotor abilities, which progressed to a complete inability to walk in the following years.
“All 14 reported patients exhibited reduced psychomotor abilities, which progressed to a complete inability to walk in the following years”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
Delayed language development was reported in five ACBD5-deficient patients.
“and delayed language development in five (Ferdinandusse et al., 2017; Bartlett et al., 2021; Gorukmez et al., 2022; Hasturk et al., 2024; Al Shamsi et al., 2025; Supplementary Table 1).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
To date, eight publications have reported on 16 patients with ACBD5 deficiency.
“To date, eight publications have reported on 16 patients with ACBD5 deficiency”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
Microcephaly was observed in six RDLKD individuals.
“Microcephaly was observed in six individuals (Ferdinandusse et al., 2017; Al Shamsi et al., 2025), while four patients were significantly underweight (Al Shamsi et al., 2025).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
One RDLKD patient was born with a cleft palate.
“Additionally, one patient was born with a cleft palate (Ferdinandusse et al., 2017; Supplementary Table 1).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
ACBD5 is specifically required for β-oxidation of VLCFA.
“reinforcing the notion that ACBD5 is specifically required for β-oxidation of VLCFA”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
No abnormalities in phytanic acid α-oxidation were detected in ACBD5-deficient patient fibroblasts.
“No abnormalities in phytanic acid α-oxidation were detected, reinforcing the notion that ACBD5 is specifically required for β-oxidation of VLCFA (Ferdinandusse et al., 2017; Yagita et al., 2017).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
Knockout of ACBD5 in HeLa and other mammalian cells did not affect pexophagy.
“knockout of ACBD5 in HeLa and other mammalian cells did not affect pexophagy (Ferdinandusse et al., 2017; Kors et al., 2024).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
These mouse models validate the impaired peroxisomal β-oxidation capacity previously demonstrated in patient-derived fibroblasts.
“These models thus validate the impaired peroxisomal β-oxidation capacity previously demonstrated in patient-derived fibroblasts (Ferdinandusse et al., 2017; Yagita et al., 2017).”
From The neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models (2025) · cites this paper as Ferdinandusse et al., 2017
Other features of ataxia, dysarthria, cleft palate, facial dysmorphisms, progressive microcephaly, and seizures are reported sporadically in ACBD5-related retinal dystrophy with leukodystrophy.
“Other features of ataxia, dysarthria, cleft palate, facial dysmorphisms, progressive microcephaly, and seizures are reported sporadically (Abu-Safieh et al., 2013;Bartlett et al., 2021;Ferdinandusse et al., 2017;Gorukmez et al., 2022).”
From <scp>ACBD5</scp>‐related retinal dystrophy with leukodystrophy due to novel mutations in <i>ACBD5</i> and with additional features including ovarian insufficiency (2024) · cites this paper as Ferdinandusse et al., 2017
Early motor development was normal in this case, but can be variable, with both normal and delayed milestones reported in other cases.
“Early motor development was normal in our case, but can be variable, with both normal and delayed milestones reported in other cases (Abu-Safieh et al., 2013;Bartlett et al., 2021;Ferdinandusse et al., 2017;Gorukmez et al., 2022).”
From <scp>ACBD5</scp>‐related retinal dystrophy with leukodystrophy due to novel mutations in <i>ACBD5</i> and with additional features including ovarian insufficiency (2024) · cites this paper as Ferdinandusse et al., 2017
Only seven cases of ACBD5-related retinal dystrophy with leukodystrophy have been reported to date, including one other case diagnosed in adulthood.
“Only seven cases of ACBD5-related retinal dystrophy have been reported in the literature to date, including one other case diagnosed in adulthood.”
From <scp>ACBD5</scp>‐related retinal dystrophy with leukodystrophy due to novel mutations in <i>ACBD5</i> and with additional features including ovarian insufficiency (2024) · cites this paper as Ferdinandusse et al., 2017
ACBD5-related retinal dystrophy with leukodystrophy is a peroxisomal disorder due to deficiency of ACBD5.
“Acyl-CoA-binding domain-containing protein 5-related retinal dystrophy with leukodystrophy (ACBD5) is a peroxisomal disorder due to deficiency of ACBD5.”
From <scp>ACBD5</scp>‐related retinal dystrophy with leukodystrophy due to novel mutations in <i>ACBD5</i> and with additional features including ovarian insufficiency (2024) · cites this paper as Ferdinandusse et al., 2017
Rod-cone dystrophy, delayed or regression of motor development, progressive cognitive decline, and imaging features of a progressive leukodystrophy are common features of ACBD5-related retinal dystrophy with leukodystrophy.
“Rod-cone dystrophy, delayed or regression of motor development, progressive cognitive decline, and imaging features of a progressive leukodystrophy are common features (Abu-Safieh et al., 2013;Bartlett et al., 2021;Ferdinandusse et al., 2017;Gorukmez et al., 2022).”
From <scp>ACBD5</scp>‐related retinal dystrophy with leukodystrophy due to novel mutations in <i>ACBD5</i> and with additional features including ovarian insufficiency (2024) · cites this paper as Ferdinandusse et al., 2017
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133 · see citing works
Biochemistry of mammalian peroxisomes revisited
Wanders, R. J. A., & Waterham, H. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133329 · Cited by 995 · see citing works
Self-citationProteomic Analysis of Rat Liver Peroxisome
Kikuchi, M., Hatano, N., Yokota, S., Shimozawa, N., Imanaka, T., & Taniguchi, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305623200 · Cited by 258 · see citing works
Wiese, S., Gronemeyer, T., Ofman, R., Kunze, M., Grou, C. P., Almeida, J. A., Eisenacher, M., Stephan, C., Hayen, H., Schollenberger, L., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700169-mcp200 · Cited by 231 · see citing works
Self-citationClinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency
Ferdinandusse, S., Denis, S., Hogenhout, E. M., Koster, J., van Roermund, C. W. T., IJlst, L., Moser, A. B., Wanders, R. J. A., & Waterham, H. R. (2007) · Human Mutation · doi:10.1002/humu.20535 · Cited by 156 · see citing works
Peroxisomal Atg37 binds Atg30 or palmitoyl-CoA to regulate phagophore formation during pexophagy
Nazarko, T. Y., Ozeki, K., Till, A., Ramakrishnan, G., Lotfi, P., Yan, M., & Subramani, S. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201307050 · Cited by 99 · see citing works
Kemp, S., Valianpour, F., Mooyer, P. A. W., Kulik, W., & Wanders, R. J. A. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038539 · Cited by 40 · cited 1× · see citing works
“mass spectrometry essentially as previously described,[20] but with D3-C22:0 instead of D3-C24:0.”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Organelle interplay-peroxisome interactions in health and disease.
Schrader, M., Kamoshita, M., & Islinger, M. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12083 · Cited by 149 · see citing works
Self-citationPeroxisomal ABC Transporters: An Update
Tawbeh, A., Gondcaille, C., Trompier, D., & Savary, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116093 · Cited by 68 · see citing works
Genome sequencing in persistently unsolved white matter disorders
Helman, G., Lajoie, B. R., Crawford, J., Takanohashi, A., Walkiewicz, M., Dolzhenko, E., Gross, A. M., Gainullin, V. G., Bent, S. J., Jenkinson, E. M., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50957 · Cited by 39 · see citing works
Self-citationPeroxisomes and their central role in metabolic interaction networks in humans.
Wanders, R. J. A., Waterham, H. R., & Ferdinandusse, S. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-13-2233-4_15 · Cited by 31 · see citing works
Self-citationKors, S., Schuster, M., Maddison, D. C., Kilaru, S., Schrader, T. A., Costello, J. L., Islinger, M., Smith, G. A., & Schrader, M. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119843 · Cited by 12 · see citing works
Self-citationRudaks, L. I., Triplett, J., Morris, K., Reddel, S., & Worgan, L. (2024) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63433 · Cited by 7 · see citing works
“Early motor development was normal in our case, but can be variable, with both normal and delayed milestones reported in other cases (Abu-Safieh et al., 2013; Bartlett et al., 2021; Ferdinandusse et al., 2017; Gorukmez et al., 2022).”
BackgroundInfluentialThe neurological pathology of peroxisomal ACBD5 deficiency – lessons from patients and mouse models
Dawes, M. L., Haberlander, J. P., Islinger, M., & Schrader, M. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1602343 · Cited by 7 · see citing works
Self-citation
- Authors
- Ferdinandusse, S., Falkenberg, K. D., Koster, J., Mooyer, P. A., Jones, R., van Roermund, C. W. T., Pizzino, A., Schrader, M., Wanders, R. J. A., Vanderver, A., & Waterham, H. R.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Kennedy Krieger Institute (US)
- Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands
- Children's National (US)
- University of Exeter (GB)
- Corresponding author
- Ferdinandusse, Sacha
- ORCID
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2016-10-31
- Volume
- 54
- Issue
- 5
- Pages
- 330-337
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2531843007
- Cited by
- 120
- References
- 7
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 10 · 2023: 13 · 2022: 14 · 2021: 10 · 2020: 20 · 2019: 12 · 2018: 14 · 2017: 8
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Journal of Medical Genetics (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K006231/1, BB/N01541X/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- peroxisomal beta-oxidation, pexophagy, retinal dystrophy, white matter disease, leukodystrophy, syndromic cleft palate, ataxia, peroxisomal disorders
- MeSH terms
- Acyl Coenzyme A, Autophagy, Child, Preschool, Fatty Acids, Female, Fibroblasts, Genetic Complementation Test, HeLa Cells, Humans, Infant, Magnetic Resonance Imaging, Membrane Proteins, Skin, DNA, Complementary, Peroxisomes, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review